The Urothelial Carcinoma Diagnostics Market To Witness Splendid Growth At The Rate Of 11% From 2020-2030

1
Urothelial Carcinoma Diagnostics Market
Report Id PMRREP14128 Category Life Science
Healthcare
2
About Persistence Market Research
Customized Research
Persistence Market Research(Persistence Market
Research) is a premier provider of syndicated
research reports, custom research reports, and
consulting services. We deliver a complete
packaged solution, which combines current market
intelligence, statistical anecdotes, technology
inputs, valuable growth insights, aerial view of
the competitive framework, and future market
trends. We provide research services at a global
as well as regional level key regions include
GCC, ASEAN, and BRIC. Our offerings cover a broad
spectrum of industries including Chemicals,
Materials, Energy, Technology, Healthcare, and
Retail. We have a global presence with delivery
centers across India specializing in providing
global research reports and country research
reports. Persistence Market Research is
headquartered out of London, U.K., with a
state-of-the-art delivery center located in Pune,
India. We combine our knowledge and learning from
every corner of the world to distill it to one
thing the perfect solution for our client.
Syndicated Research
Investment Research
Social Media Research
Research Capabilities
Sector Coverage

• Customized Research
• Syndicated Research
• Investment Research
• Social Media Research

• Automotive and Transportation
• Electronics, Semiconductor, and ICT
• Retail and Consumer Products
• Industrial Automation and Equipment

• Chemicals Materials
• Food and Beverages
• Services and Utilities
• Energy, Mining, Oil, and Gas

Subscription Information
For detailed subscription information please
contact Website www.persistencemarketresearch.co
m For sales queries or new topics email us on
sales_at_persistencemarketresearch.com
3
The Urothelial Carcinoma Diagnostics Market To
Witness Splendid Growth At The Rate Of 11 From
2020-2030

• According to World Health Organization (WHO)
  estimates, every year, 3.8 Mn new cases of
  urothelial carcinoma occur around the world, with
  the recurrence rate being nearly 30-50. However,
  early detection by use of modern diagnostics
  enables quick medical decision-making and
  consequent treatment for urothelial carcinoma.
  Accuracy in urothelial carcinoma diagnostics
  plays a significant role in the reduction of
  treatment costs.
• Moreover, increased demand for treatment of
  urothelial carcinoma is a key driver for
  increasing revenue inflow from diagnostic tests
  and procedures. However, development of effective
  urothelial carcinoma screening methods will play
  a significant role in the early detection and
  subsequent reduction in mortality rates.
  Furthermore, technological advancements in
  diagnostic methods such as the adoption of
  diagnostic imaging procedures, rapid molecular
  diagnostic kits, and use of biomarker testing in
  urothelial carcinoma screening programs are some
  other factors that will aid the growth of the
  urothelial carcinoma diagnostics market.
• According to the latest report published by PMR,
  the global urothelial carcinoma diagnostics
  market was valued at US 1 Bn in 2020, and is
  expected to progress at a CAGR of over 11 during
  the forecast period (20202030).

Get Sample Copy of this Report _at_ https//www.persi
stencemarketresearch.com/samples/14128
4
What Does the Report Cover?
Key players in the urothelial carcinoma
diagnostics market are looking forward to
strengthening their product portfolios through
the launch of new products. For instance,
in 2017, Roche received FDA approval for the
complementary PD-L1 (SP263) biomarker test in
urothelial carcinoma. In August, 2018, Agilent
Technologies, Inc announced that the US Food and
Drug Administration approved its Dako PD-L1 IHC
22C3 pharmDx assay for expanded use as a
companion diagnostic test for Mercks anti-PD1
immunotherapy Keytruda (pembrolizumab) for
urothelial carcinoma. Various players in the
urothelial carcinoma diagnostics market are
focusing on growth strategies such as
acquisitions and partnerships. For example,
in 2020, Thermo Fisher Scientific signed an
agreement with Janssen to co-develop companion
diagnostics for cancer. Persistence Market
Research offers a unique perspective and
actionable insights on the urothelial carcinoma
diagnostics market in its latest study,
presenting historical demand assessment
of 20152019 and projections for 20202020, on
the basis of product type (reagents and kits,
instruments), test type (urinalysis test,
molecular diagnostic test, biomarker test,
imaging test, cytoscopy, ureteroscopy), and end
user (hospitals, diagnostic laboratories,
research and academic institutes, clinical
research organizations), across seven key
regions.
Access Full Report _at_ https//www.persistencemarket
research.com/checkout/14128
5
(No Transcript)